SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment by Abdel-Fatah, Tarek M.A. et al.
1 
 
SHON expression predicts response and relapse risk of breast cancer patients 
after anthracycline-based combination chemotherapy or tamoxifen treatment 
 
Tarek M. A. Abdel-Fatah1,2, Reuben J. Broom3, Jun Lu4, Paul M. Moseley1, Baiqu 
Huang5, Lili Li6, Suling Liu7, Longxin Chen8, Runlin Z. Ma9, Wenming Cao10, Xiaojia 
Wang10, Yan Li11, Jo K. Perry12, Mohammed Aleskandarany13, Christopher C. 
Nolan13, Emad A. Rakha14, Peter E. Lobie15, Stephen Y. T. Chan1, Ian O. Ellis13, Le-
Ann Hwang16, David P. Lane16, Andrew R. Green13 and Dong-Xu Liu4,11 
 
1Department of Clinical Oncology, University of Nottingham and Nottingham 
University Hospitals NHS Trust, Nottingham, UK; 2National Liver Institute, Menoufyia 
University, Egypt; 3Auckland City Hospital, Auckland, New Zealand; 4The Institute of 
Genetics and Cytology, Northeast Normal University, Changchun, China; 5The Key 
Laboratory of Molecular Epigenetics of Ministry of Education (MOE), Northeast 
Normal University, Changchun, China; 6Department of Bone and Soft Tissue 
Tumors, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; 
7Fudan University Shanghai Cancer Center & Institutes of Biomedical Sciences, 
Shanghai Medical College, Key Laboratory of Breast Cancer in Shanghai, Cancer 
Institutes, Fudan University, Shanghai, China; 8Laboratory of Molecular Biology, 
Zhengzhou Normal University, Zhengzhou, China; 9Institute of Genetics and 
Developmental Biology, Chinese Academy of Sciences, Beijing, China; 10Department 
of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China; 11The Centre for 
Biomedical and Chemical Sciences, School of Science, Faculty of Health and 
Environmental Sciences, Auckland University of Technology, Auckland, New 
Zealand; 12Liggins Institute, University of Auckland, Auckland, New Zealand; 
2 
 
13Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, 
School of Medicine, University of Nottingham, Nottingham City Hospital, Nottingham, 
UK; 14Department of Histopathology, School of Medicine, Nottingham University 
Hospitals NHS Trust, University of Nottingham, Nottingham, UK; 15Tsinghua 
Berkeley Shenzhen Institute, Tsinghua University, Shenzhen, Guangdong, China 
and 16p53 Laboratory, Biomedical Sciences Institutes, Agency for Science, 
Technology and Research (A*STAR), Singapore 
 
 
*Correspondence: Associate Professor Dong-Xu Liu, the Centre for Biomedical and 
Chemical Sciences, School of Science, Faculty of Health and Environmental 
Sciences, Auckland University of Technology, C-42, Private Bag 92006, Auckland 
1142, New Zealand. Tel: +64-9-921 9999 ext. 6722; E-mail: dong-xu.liu@aut.ac.nz; 
and Assistant Professor Andrew R. Green, Nottingham Breast Cancer Research 
Centre, Division of Cancer and Stem Cells, School of Medicine, University of 
Nottingham, Nottingham City Hospital, Nottingham NG5 1PB, UK. Tel: +44-115 823 
1407; E-mail: andrew.green@nottingham.ac.uk 
 
 
Running title: SHON predicts treatment response and relapse risk 
 
Keywords: SHON, biomarker, breast cancer, estrogen receptor, endocrine therapy, 
chemotherapy 
 
  
3 
 
Abstract 
 
BACKGROUND: SHON nuclear expression (SHON-Nuc+) was previously reported 
to predict clinical outcomes to tamoxifen therapy in ERα+ breast cancer (BC). Herein 
we determined if SHON expression detected by specific monoclonal antibodies could 
provide a more accurate prediction and serve as a biomarker for anthracycline-
based combination chemotherapy (ACT). 
METHODS: SHON expression was determined by immunohistochemistry in the 
Nottingham early-stage-BC cohort (n=1,650) who, if eligible, received adjuvant 
tamoxifen; the Nottingham ERα- early-stage-BC (n=697) patients who received 
adjuvant ACT; and the Nottingham locally advanced-BC cohort who received pre-
operative ACT with/without taxanes (Neo-ACT, n=120) and if eligible, 5-year 
adjuvant tamoxifen treatment. Prognostic significance of SHON and its relationship 
with the clinical outcome of treatments were analysed. 
RESULTS: As previously reported, SHON-Nuc+ in high risk/ERα+ patients was 
significantly associated with a 48% death risk reduction after exclusive adjuvant 
tamoxifen treatment compared with SHON-Nuc- [HR(95%CI)=0.52(0.34-0.78), 
p=0.002]. Meanwhile, in ERα- patients treated with adjuvant ACT, SHON cytoplasmic 
expression (SHON-Cyto+) was significantly associated with a 50% death risk 
reduction compared with SHON-Cyto- [HR(95%CI)=0.50(0.34-0.73), p=0.0003]. 
Moreover, in patients received Neo-ACT, SHON-Nuc- or SHON-Cyto+ was 
associated with an increased pathological complete response (pCR) compared with 
SHON-Nuc+ [21% vs 4%; OR(95%CI)=5.88(1.28-27.03), p=0.012], or SHON-Cyto- 
[20.5% vs 4.5%; OR(95%CI)=5.43(1.18-25.03), p=0.017], respectively. After 
receiving Neo-ACT, patients with SHON-Nuc+ had a significantly lower distant 
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relapse risk compared to those with SHON-Nuc- [HR(95%CI)=0.41(0.19-0.87), 
p=0.038], whereas SHON-Cyto+ patients had a significantly higher distant relapse 
risk compared to SHON-Cyto- patients [HR(95%CI)=4.63(1.05-20.39), p=0.043]. 
Furthermore, multivariate Cox regression analyses revealed that SHON-Cyto+ was 
independently associated with a higher risk of distant relapse after Neo-ACT and 5-
year tamoxifen treatment [HR(95%CI)=5.08(1.13-44.52), p=0.037]. The interaction 
term between ERα status and SHON-Nuc+ (p=0.005), and between SHON-Nuc+ and 
tamoxifen therapy (p=0.007), were both statistically significant. 
CONCLUSION: SHON-Nuc+ in tumours predicts response to tamoxifen in ERα+ BC 
while SHON-Cyto+ predicts response to ACT. 
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BACKGROUND 
 
Annually there are approximately 2.1 million new cases of female breast cancer (BC) 
in the world.1 Despite improved treatment options, an estimated 626,000 women still 
die from this disease each year.1 BC is not one single disease but consists of a 
complex group of diseases that are highly heterogeneous in terms of genotype, 
phenotype, sensitivity to treatment, and clinical outcome.2 The success of improved 
personalized BC therapy relies on the development of robust and accurate 
biomarkers to guide clinical decision-making in the management of BC. 
 
While targeted therapies are preferable to chemotherapy as first-line treatment for 
patients with estrogen receptor α positive (ERα+) and HER2-positive (HER2+) 
metastatic BC, chemotherapy is often the initial therapeutic modality of choice for 
triple negative, and locally advanced or metastatic BC. A meta-analysis of 123 
randomized trials involving over 100,000 patients over 40 years has concluded that 
standard chemotherapy reduced two-year recurrence rates by 50%, eight-year 
recurrence rates by approximately one-third, and overall mortality rates by 20-25%.3 
However, one obstacle to greater success with chemotherapy treatment is drug 
resistance (acquired or/and intrinsic).4 Currently, there is still no definitive 
methodology to distinguish tumours that will or will not respond to chemotherapies.5,6 
 
SHON is a recently identified secreted hominoid-specific oncogene in BC.7 Forced 
expression of SHON in BC cell lines significantly increases cell proliferation and 
survival, promotes anchorage independent growth and enhances cell 
migration/invasion.7 Furthermore, SHON enhances the oncogenicity of BC cells in 
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xenograft models and is sufficient to oncogenically transform MCF10A human 
normal breast cells.7 It has also been shown that SHON regulates epithelial-
mesenchymal transition (EMT) through TGF-β signalling in BC cells.8 More 
importantly, SHON is an estrogen inducible gene and its expression in ERα+ breast 
tumours has been shown to be a potential prognostic biomarker for predicting a 
patient's response to endocrine therapy.7 On the other hand, SHON expression is 
also observed in ERα- BC cell lines such as BT549 and MDA-MB-231, as well as in 
ERα- BC tissues.7 However, the clinical implication of SHON expression in ERα- 
breast tumours remains unknown. 
 
In the present study, we analysed SHON protein expression in a large cohort of 
breast tumours by immunohistochemical (IHC) staining using a newly generated 
anti-SHON monoclonal antibody and determined the relationship of SHON 
expression with the clinical outcome of chemotherapy-treated patients in another two 
independent cohorts. We not only validated that SHON nuclear expression in tumour 
cells was an accurate predictive biomarker for ERα+ patients who received 
tamoxifen, but also identified that SHON cytoplasmic expression in ERα- tumours 
was able to predict the response of a patient to anthracycline-based treatment. 
 
 
MATERIALS AND METHODS 
 
The Nottingham University Hospitals early stage BC cohort 
SHON protein expression was examined in a consecutive series of 1,650 patients 
with primary invasive breast carcinomas who were diagnosed between 1986 and 
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1999 and entered into the Nottingham University Hospitals (NUH) early stage BC 
(NUH-ES-BC) cohort. All patients were treated uniformly in a single institution and 
have been investigated in a wide range of biomarker studies.9-11 Supplementary 
Table S1 summarizes the patient demographics. Patients received standard surgery 
(mastectomy or wide local excision) with radiotherapy. Prior to 1989, patients did not 
receive either endocrine therapy or chemotherapy. After 1989, adjuvant-therapy was 
scheduled on the basis of the Nottingham Prognostic Index (NPI), ERα and 
menopausal status. Patients with NPI scores <3.4 (low risk) did not receive adjuvant 
therapy. Pre-menopausal patients with NPI scores ≥ 3.4 (high risk) received 
Cyclophosphamide, Methotrexate and 5-Flourouracil (CMF) combination 
chemotherapy, and patients with ERα+ tumour were also received tamoxifen for 5 
years. The minimum follow-up period was 123 months and the BC specific survival 
(BCSS) was used as a primary endpoint. 
 
The NUH ERα- early stage BC cohort 
In order to assess the value of SHON protein expression as a biomarker in the 
context of current combination cytotoxic chemotherapy, we also analysed its 
expression in the NUH ERα- early stage BC (NUH-ERα-ESBC) cohort. It is an 
independent series of 697 patients who had been diagnosed and managed at the 
same institution between 1999 and 2007, 141 of whom were treated with adjuvant 
anthracycline-based combination chemotherapy (ACT). Comprehensive follow-up 
data were available for 275 patients with BCSS as a primary endpoint (median = 89 
months, mean = 86 months; Supplementary Table S1). 
 
The NUH locally advanced BC cohort 
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The relationship between SHON protein expression and response to chemotherapy 
was evaluated by investigating its expression in the pre-chemotherapy core biopsies 
from 120 female patients with locally advanced (stage IIIA-C) primary BC (NUH-
LABC), who were treated with anthracycline-based Neo-ACT (Neo-ACT) at the 
Nottingham City Hospital between 1996 and 2012. Fifty-three percent (62/120) of the 
patients received six cycles of anthracycline-based therapy, i.e. FEC: 5-Fluorouracil 
(5-FU) 500 mg m−2, Epirubicin 75–100 mg m−2, Cyclophosphamide 500 mg m−2, on 
day 1 of a 21-day cycle, and 47% (54/120) of the patients received three cycles of 
the FEC plus three cycles of taxane (Doxetaxel; 100 mg m−2). All patients underwent 
mastectomy or breast-conserving surgery and axillary dissection, followed by 
adjuvant radiation therapy and if tumours were ERα+, 5-year tamoxifen treatment. 
The median follow-up time was 67 months (IRQ 27-81). 
 
Survival data 
Survival data including survival time, disease-free survival (DFS), and development 
of loco-regional and distant metastases (DM) were maintained on a prospective 
basis. DFS was defined as the number of months from diagnosis to the occurrence 
of recurrence or DM relapse. BCSS was defined as the number of months from 
diagnosis to the occurrence BC-related death. Survival was censored if the patient 
was still alive, lost to follow-up, or died from other causes. The study was carried out 
according to the Reporting Recommendations for Tumour Marker Prognostic Studies 
(REMARK) criteria.12 
 
Tissue microarrays and immunohistochemistry 
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Tumours were incorporated into tissue microarrays (TMAs). These were constructed 
using six replicate 0.6 mm cores from the centre and periphery of the tumours of 
each patient. 
 
We produced a mouse monoclonal antibody against the mature SHON peptide. The 
specificity of the mouse anti-SHON monoclonal antibody was determined by 
Western blot analysis and indirect immunofluorescence staining. The antibody was 
able to specifically recognize both the endogenous and forced expression of SHON 
protein in human BC cell lines (Supplementary Figure S1).  
 
The TMAs and full face sections were immunohistochemically profiled with the 
SHON monoclonal antibody and other antibodies (Supplementary Table S2) using a 
Novolink Detection kit according to the manufacturer’s protocol (Leica Microsystems) 
as we previously described.7 Sections were pre-treated by boiling in citrate buffer 
(pH 6.0) for 20 minutes, and incubated at room temperature for 60 min with the anti-
SHON monoclonal antibody at a final concentration of 4 µg/ml. Expression of HER2, 
ERα and PR was assessed according to the American Society of Clinical 
Oncology/College of American Pathologists (ASCO/CAP) guidelines.13,14 
 
To validate the use of TMAs for immuno-phenotyping, full-face sections of 40 cases 
were stained and the protein expression levels were compared. The concordance 
between TMAs and full-face sections was excellent using Cohen's kappa statistical 
test for categorical variables (kappa = 0.8). Positive and negative (omission of the 
primary antibody and IgG-matched serum) controls were included in each run. 
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Evaluation of SHON IHC staining 
Tumour cores were evaluated by two pathologists who were blinded to the 
clinicopathological characteristics of patients in two different settings. Whole field 
inspection of the core was scored and intensities of both nuclear and cytoplasmic 
staining were grouped as follows: 0=no staining, 1=weak staining, 2=moderate 
staining, 3=strong staining. The percentage of each category was estimated and the 
H-score was calculated as previously described.9 Due to intra- and inter-tumoral 
heterogeneity of staining, the average percentage was calculated. The cut-off of 
SHON cytoplasmic and nuclear staining was determined by using the median 
expression. High cytoplasmic staining was defined as the presence of H-score > 
150, whereas high nuclear staining was defined as the presence of ≥ 1% positive 
nuclear staining (Fig. 1). Intra- (kappa > 0.8; Cohen kappa test) and inter- (kappa > 
0.8; using multi-rater kappa tests) observer agreements were excellent. In cases 
where discordant results were obtained, the slides were re-evaluated by both 
pathologists together and a consensus was reached.  
 
Statistical analysis 
Data analyses were performed using SPSS statistics software (version 17, Chicago, 
IL). Where appropriate, Pearson’s Chi-square, and Student’s t-test were used. 
Significance was defined at p<0.05. 
 
Cumulative survival probabilities were estimated using the Kaplan–Meier method, 
and differences between survival rates were tested for significance using the log-
rank test. Multivariate analyses for survival were performed using the Cox 
proportional hazard model. The proportional hazards assumption was tested using 
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standard log-log plots. Hazard ratios (HR) and 95% confidence intervals (95% CI) 
were estimated for each variable. All tests were two-sided with a 95% CI, and a p 
value < 0.05 was considered to be indicative of statistical significance. A stringent p 
value <0.01 was considered to indicate statistical significance for multiple 
comparisons. 
 
 
RESULTS 
 
Sub-cellular compartmentalization of SHON protein expression 
A total of 1,299 tumours in the NUH-ES-BC cohort were suitable for the IHC analysis 
of SHON protein expression. High nuclear SHON (SHON-Nuc+) staining was 
observed in 205/1,299 (16%) tumours compared to 1,094/1,299 (84%) tumours that 
had no nuclear SHON staining (SHON-Nuc-). However, 865/1,299 (67%) tumours 
exhibited high cytoplasmic staining (SHON-Cyto+) compared with 434/1299 (33%) 
tumours that had low cytoplasmic expression (SHON-Cyto-). There was an inverse 
correlation between cytoplasmic and nuclear SHON expression (p<0.0001). The 
majority of tumours (766/1,299; 59%) were SHON-Cyto+/Nuc- phenotype. The 
percentages of SHON-Cyto-/Nuc-, SHON-Cyto-/Nuc+ and SHON-Cyto+/Nuc+ tumours 
were 25% (328/1,299), 8% (106/1,299) and 8% (99/1,299), respectively. 
 
Association of SHON nuclear expression with favourable clinicopathological 
characteristics 
SHON nuclear expression was associated with favourable clinicopathological 
features including hormone receptor (ERα+, PR+ and AR+) positivity, 4-IH luminal A 
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(ERα+/HER2-/low proliferation phenotype), tubular BC, low histological grade, low 
mitotic index, low proliferation index (Ki67), low pleomorphism, and MDM4 
overexpression (Table 1). Furthermore, SHON-Nuc+ was highly associated with high 
expression of DNA repair proteins: PARP1, TOPO2A, RECQL4 Nuclear, RECQL5, 
BLM Nuclear, CHK1, CHK2, and Phosphorylated CHK1 Nuclear (Table 1). 
 
Association of SHON cytoplasmic expression with aggressive 
clinicopathological characteristics 
SHON cytoplasmic expression was associated with aggressive clinicopathological 
features including absence of hormone receptor (ERα-, PR- and AR-) positivity, 
basal-like phenotype, ERα-/HER2-, triple negative, IDC-NST, higher histological 
grade, tubular dedifferentiation, pleomorphism, high mitotic index, higher levels of 
proliferation markers, low BCL-2, high vimentin (all p<0.001) and lymphovascular 
invasion (LVI) (p=0.025) (Table 2). 
 
SHON-Cyto+/Nuc- phenotype exhibited the most aggressive features including 
absence of hormone receptor (ERα-, PR- and AR-) positivity, triple negative, basal 
like, large size, high stage, high grade, high LVI, overexpression of HER family 
(HER1+, HER2+, HER3+ and HER4+), p53 mutation, dysregulation of both DNA 
repair and high vimentin (Table 2). 
 
SHON protein nuclear expression predicted favourable clinical outcomes of 
ERα+ BC treated with endocrine therapy 
SHON-Nuc+ in the whole NUH-ES-BC cohort was associated with prolonged BCSS 
and a reduced risk of death from BC [HR (95% CI) = 0.66 (0.55-0.80), p<0.0001] 
13 
 
(Fig. 2a), in the low risk patients [NPI<3.4; HR (95% CI) = 0.53 (0.32-0.88), p=0.015] 
(Fig. 2b), and in the ERα+ subgroup [HR (95% CI) = 0.61 (0.48-0.76), p<0.0001] (Fig. 
2c). 
 
In high risk (NPI≥3.4)/ERα+ patients who did not receive tamoxifen treatment, 
tumours with or without SHON nuclear protein expression had a similar BCSS rate 
[HR (95% CI) = 1.00 (0.73-1.37), p=0.998] (Fig. 2d). Meanwhile, SHON nuclear 
protein expression positivity was very significantly associated with better survival and 
a 48% lower risk of death in tamoxifen-treated patients [HR (95% CI) = 0.52 (0.34-
0.78), p=0.002] compared with SHON nuclear protein expression negativity (Fig. 2e). 
In high risk/ERα+ subgroups, if the tumours were also SHON-Nuc+, tamoxifen 
treatment resulted in improved survival and a reduced risk of death from BC by 79% 
[HR (95% CI) = 0.21 (0.08-0.56), p=0.002] (Fig. 2f), whereas if the tumours were 
SHON-Nuc-, administration of tamoxifen had no impact on the survival [HR (95% CI) 
= 0.85 (0.63-1.16), p=0.302] (Fig. 2g). This result is consistent with our previous 
observation that SHON nuclear protein expression is a predictor of patient response 
to tamoxifen treatment in BC.7 
 
SHON protein cytoplasmic expression predicted worse clinical outcomes of 
BC 
SHON-Cyto+ in the whole NUH-ES-BC cohort was associated with shorter BCSS 
and an increased risk of death from BC [HR (95% CI) = 1.24 (1.10-1.39), p=0.001] 
(Fig. 3a), and the ERα+ subgroup [HR (95% CI) = 1.22 (1.06-1.41), p=0.007] (Fig. 
3b). However, there was no association between the impact of tamoxifen on patient 
survival and SHON cytoplasmic expression in the ERα+ subgroup (Figs. 3c,d). 
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SHON protein cytoplasmic expression predicted clinical outcomes of ERα- BC 
treated with anthracycline-based chemotherapy 
In the ERα- BC subgroup, there was no association between SHON-Cyto+ and 
clinical outcomes in the NUH-ERα-ESBC cohort (Fig. 4a). However, SHON 
cytoplasmic expression predicted better BCSS in those patients who received 
anthracycline-based combination chemotherapy. As shown in Fig. 4b, SHON-Cyto+ 
was associated with a trend of shorter survival in ERα- patients who did not receive 
any chemotherapy, though it was not statistically significant [HR (95% CI) = 1.24 
(0.98-1.56), p=0.076]. In contrast, in anthracycline-based combination-treated 
patients with ERα- tumours, SHON-Cyto+ was highly significantly associated with 
better BCSS and a lower risk of death compared with SHON-Cyto- [HR (95% CI) = 
0.50 (0.34-0.73), p=0.0003] (Fig. 4c). Exposure to anthracycline resulted in improved 
BCSS and a reduced risk of death from BC in tumours with SHON-Cyto+ [HR (95% 
CI) = 0.30 (0.17-0.53), p=0.00003] (Fig. 4d), whereas in those with SHON-Cyto-, 
exposure to anthracycline was associated with a trend of shorter survival and a 
higher risk of death, though it was not statistically significant [HR (95% CI) = 1.84 
(0.90-3.75), p=0.096] (Fig. 4e). The interaction term between SHON-Cyto expression 
and anthracycline chemotherapy was highly significant (p<0.001). These results 
indicate that SHON cytoplasmic protein expression was able to predict the BCSS of 
patients with ERα- tumours treated with anthracycline- based chemotherapy. 
 
The relationship between SHON protein expression and distant relapse risks 
after receiving Neo-ACT and 5-year adjuvant tamoxifen 
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In the NUH-LABC cohort, BC patients received the Neo-ACT chemotherapy followed 
by a 5-year adjuvant tamoxifen treatment if the tumours were ERα+. Patients with 
high nuclear SHON protein expression had a significantly lower distant relapse risk 
compared to low nuclear SHON protein expression [20% vs 39%; HR (95% CI) = 
0.41 (0.19-0.87), p=0.02; Fig. 5a], whereas high SHON cytoplasmic expression had 
a significant higher distant relapse risk compared to low SHON cytoplasmic 
expression [44% vs 22%; HR (95% CI) = 2.13 (1.01-4.53), p=0.046; Fig. 5b]. 
Moreover; a multivariate Cox regression model controlling for other validated 
prognostic factors and systemic therapy revealed that high cytoplasmic SHON 
expression was independently associated with a higher risk of distant relapse after 
the Neo-ACT and 5-year tamoxifen treatment [HR (95% CI) = 5.08 (1.13-44.52), 
p=0.037]. The interaction term between ERα status and SHON nuclear expression 
was statistically significant in determining distant metastasis-free survival (p=0.005). 
In addition, the interaction term between SHON nuclear expression and tamoxifen 
therapy was also highly significant (p=0.007) (Table 3). 
 
The relationship between SHON protein expression and response to Neo-ACT 
chemotherapy 
We further investigated the association between SHON protein expression and the 
pathological complete response (pCR) in the NUH-LABC cohort, in which 117 
patients had response data and 15% (17/117) achieved a pCR. SHON nuclear 
expression was detected in 39% (46/117) of the pre-chemotherapy core biopsies, 
whereas high cytoplasmic staining was observed in 62% (73/117) of the biopsies. No 
SHON expression was seen in 14.5% (17/117) of the biopsies, while 12% (14/117) 
showed both high nuclear and cytoplasmic staining, 50% (59/117) no nuclear but 
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high cytoplasmic staining, and 23% (27/117) high nuclear but low cytoplasmic 
staining. Low SHON nuclear protein expression was associated with an increased 
proportion of patients achieving a pCR [21% (15/71) of the patients] compared with 
high SHON nuclear protein expression [4% (2/46) of the patients; OR (95% CI) = 
5.88 (1.28–27.2203), p=0.012]. High SHON cytoplasmic protein expression was 
associated with an increased proportion of patients achieving a pCR [21% (15/73) of 
the patients] compared with low SHON cytoplasmic protein expression [5% (2/44) of 
the patients; OR (95% CI) = 5.43 (1.18–25. 03), p=0.017]. Multivariate logistic 
regression analyses showed that SHON high cytoplasmic staining, like SPAG5 
overexpression,10 independently predicted the sensitivity to ACT (i.e., a higher pCR) 
[OR (95% CI) = 5.22 (1.03-26.47), p=0.046] (Table 4)]. 
 
 
DISCUSSION 
 
SHON is a recently identified novel secreted hominoid-specific oncoprotein in BC. 7 
We had previously generated a SHON polyclonal antibody and used it to perform 
IHC in the well-characterized Nottingham Tenovus primary breast carcinoma 
series.9-11 In that study, we demonstrated that SHON nuclear expression in breast 
tumours predicted the clinical outcome of patients who received tamoxifen in a high 
risk and ERα+ cohort.7 We have now developed a SHON monoclonal antibody and 
with it, we have not only validated our previous findings, but have also observed that 
SHON nuclear expression is actually an absolute determinant of survival outcomes 
with tamoxifen. Furthermore, we demonstrated that SHON cytoplasmic expression in 
ERα- tumours predicted clinical outcomes in patients receiving anthracycline-based 
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chemotherapy. Given that tamoxifen and chemotherapy resistance severely limits 
successful management of BC, SHON may serve as a biomarker for selection of 
patients for treatment in the clinic. 
 
It is still unclear how SHON nuclear expression is able to impact on the efficacy of 
tamoxifen therapy. SHON is an estrogen-regulated gene and the pure ERα 
antagonist ICI 182,780 partially attenuates SHON-stimulated growth promotion in 
MCF-7 breast cancer cells, indicating that SHON signalling is at least, in part, 
mediated by ERα.7 However, ERα-regulated functions are thought to play a pivotal 
role in determining the response to anti-estrogen therapy. Several of the genes that 
the Oncotype DX test measures are ERα-regulated genes, including PR, BCL-2 and 
SCUBE2.15,16 Therefore, ERα-driven genes may be of particular interest for the 
development of molecular biomarkers to predict response to endocrine treatment. It 
has been shown that forced expression of SHON increases phosphorylation of AKT 
and p44/42 MAPK, and increases the expression of BCL-2 and NF-κB to mediate the 
oncogenicity of SHON.7 Therefore, SHON may modulate ERα signalling through the 
activation of p44/42 MAPK, PI3K/AKT/mTOR pathways and NF-κB transcriptional 
activation of BCL-2 (Fig. 6). SHON presumably functions in an autocrine/paracrine 
manner as other secreted growth factors. Secreted SHON may bind to and activate 
a yet-unknown cell surface receptor, which consequently activates the PI3K/AKT and 
MAPK pathways that are linked to the action of ERα, including transcription of target 
genes. Nuclear SHON may also be directly involved in estrogen independent 
signalling of ERα, through modulation of the binding of ERα to other transcription 
factors e.g. SP-1 and AP-1. It has now been shown that many secreted growth 
factors, including prolactin, growth hormone, epidermal growth factor (EGF), 
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interferon gamma and Schwannoma-derived growth factor, are located both in the 
cytoplasm and in the nucleus.17 Such differential subcellular localisations are often 
associated with distinctive functions. It is observed that some of these factors e.g. 
FGFs contain nuclear localisation signals, but others do not. In the case of FGF-1, it 
is the exogenous, rather than intracellular, pools of FGF-1 that enter the nucleus.18,19 
Cytosolic accumulation and subsequent nuclear import of FGF-1 require PI3K 
signalling, and nuclear translocation of FGF-1 is dependent upon acidic vesicular 
pumps. Once in the nucleus, nuclear FGF-1 stimulates DNA synthesis, independent 
of cell surface signalling. Moreover, multiple growth factor receptors have also been 
found in the nucleus, including the prolactin receptor, growth hormone receptor and 
EGF receptors in the form of both intact and cleaved membrane associated 
receptors. ERα itself is a nuclear receptor. Therefore, it is possible that exogenous 
and/or intracellular pools of SHON may directly enter the nucleus, and thus enhance 
the transcriptional activity of ERα (Fig. 6). However, it is not yet clear how SHON 
enters the nucleus. Of note, SHON has also been shown to promote EMT through 
the TGF-β pathway via the mediation of SMAD2/3 signalling.8 Activated SMAD2/3 
binds SMAD4 in cytoplasm, followed by the translocation of the SMAD2/3/4 complex 
into the nucleus to regulate the transcription of TGF-β-induced genes.20,21 Upon 
exposure to tamoxifen, SMAD4 binds ERα and serves as a transcription corepressor 
for ERα.22,23 Therefore, SHON nuclear expression could be a determinant of an 
active ERα signalling complex so that tamoxifen can effectively block ERα signalling. 
It is also possible that its nuclear localization facilitates TGF-β-SMAD4 and ERα 
cross talk and inhibits ERα-mediated gene transcription (Fig. 6). 
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Biomarkers play a fundamental role in the personalisation of clinical breast cancer 
care for improved treatment outcomes. Despite more than a decade’s effort to 
develop new breast cancer biomarkers, only three biomarker tests (ERα, PR and 
HER2) are currently mandatory for those diagnosed with breast cancer.24 Other 
multigene tests are either useful only in a subgroup of breast cancers, including 
Oncotype DX, Prosigna, MammaPrint and EndoPredict, or simply investigational.25 
They are commonly used to provide complementary prognostic information to 
clinicopathological features and predict chemotherapy benefit in early stage hormone 
receptor-positive and HER2-negative BC.26-28 The development of multigene tests 
usually face issues such as insufficiently high levels of evidence, overfitting 
computational models and false discovery rates.29 In addition, they often do not yield 
significant improvement in predictive accuracy over the well-established pathological 
parameters such as histological grade.30 This is because these gene-expression 
biomarkers share common molecular pathways centred on cell proliferation and cell 
cycle regulation, which are the key components of the well-established pathological 
parameters.30 Moreover, MammaPrint and EndoPredic have been found to give 
different treatment recommendations for a portion of patients and cannot be used 
interchangeably,31 while Oncotype DX and MammaPrint offer different prognostic 
information to the same patients.32 Another issue with multigene tests is that some 
patients will still have an “intermediate” risk score, leading to an inconclusive 
prognosis,26 though chemotherapy may be surely spared in patients at intermediate 
recurrence scores as shown in the recent prospective TAILORx trail.28 Furthermore, 
although Oncotype DX can identify a group of patients with excellent prognosis when 
treated with adjuvant tamoxifen,15,16 it may provide no new biological insights into 
tamoxifen response than the simple measurement of ER and PR levels by the easy 
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conventional IHC.33 It has now been demonstrated that a well selected single gene, 
such as SPAG5 10, ESPL1 34 or Ki67 35, may be a better indicator of proliferation 
than the mixture of suboptimal proliferation genes included in the multigene tests.36 
Such a protein biomarker would easily be implemented in the clinic as a routine test 
using conventional IHC techniques that have been used for ER at a fraction of the 
high cost associated with multigene tests.  
 
In the current study, we also demonstrated that SHON cytoplasmic expression 
predicted better survival to adjuvant ACT chemotherapy in the ERα- cohort, a higher 
pCR after receiving pre-operative ACT chemotherapy (chemotherapy 
responsiveness), and poor survival after 5-year tamoxifen treatment. In addition, 
SHON nuclear expression predicted favourable survival to adjuvant endocrine 
therapies, and a lower pCR after receiving pre-operative ACT chemotherapy 
(chemotherapy resistance). It is worthy of note that achieving a pCR after receiving 
neoadjuvant chemotherapy provides important prognostic information and is 
considered a surrogate endpoint for event-free survival in ERα- or triple negative 
BC.37-39 In contrast, in ERα+ and HER2+ BC, the event-free survival is merely 
determined by the administration of targeting therapy: either endocrine or Herceptin 
therapy. Therefore, it was not surprising that SHON cytoplasmic expression was 
associated with a better survival outcome in our adjuvant ERα- BC cohort whereas it 
was associated with poor survival in the neoadjuvant cohort (which was 
predominantly ERα+ BC) who received preoperative chemotherapy followed by 5-
year adjuvant tamoxifen although SHON cytoplasmic expression was associated 
with a higher pCR. Similarly, although SHON nuclear expression was associated 
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with a lower pCR after receiving preoperative chemotherapy, it was associated with 
better survival after 5-year tamoxifen therapy. 
 
We previously demonstrated that SHON was also expressed in ERα- BT549 and 
MDA-MB-231 BC cells.7 The current IHC analysis also showed that SHON 
cytoplasmic expression was significantly associated with aggressive BC phenotypes. 
Clinical data have previously indicated that as anti-estrogen responsiveness 
increases, chemo-responsiveness decreases.40,41 We also showed that there was an 
inverse correlation between cytoplasmic and nuclear SHON expression in all the 
tumours. Therefore, it is consistent that nuclear SHON expression was linked to 
better survival to tamoxifen whereas cytoplasmic SHON expression was associated 
with better response to chemotherapy. High chromosomal instability and aneuploidy 
are hallmarks of malignant cells and confer vulnerability to chemotherapy.42 We 
demonstrated that SHON nuclear expression was highly associated with the 
expression of DNA repair proteins and a low proliferation index (Ki67), suggesting 
that SHON may be an important driver for genetic stability in BC, and SHON 
dysregulation could contribute to chromosomal instability. These findings are in 
agreement with previous studies that have suggested anthracycline works best in 
tumours with higher proliferation and chromosomal instability,43,44 whereas endocrine 
therapy is more effective in chromosomally stable, low proliferative BC.45 
 
In summary, our study has clearly demonstrated that SHON expression in tumours is 
a potential biomarker for tamoxifen and chemotherapy responses, depending on its 
subcellular localization. While SHON nuclear expression was able to predict patient 
outcomes to tamoxifen in ERα+ BC, SHON cytoplasmic expression could predict the 
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response to ACT chemotherapy. However, the exact mechanism for its biomarker 
utility is still unclear. Identification of a potential SHON receptor, and determining the 
role of SHON in ERα- BC cells will be the next priority in delineating its mechanisms 
of action. Multicentre prospective studies are required for confirmation and validation 
before SHON can be used as a clinical biomarker. 
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Figure legends 
Fig. 1 Microphotographs of SHON expression in representative breast cancer 
TMA cores. SHON expression was determined by IHC using a SHON mouse 
monoclonal antibody. ERα, estrogen receptor α. 
Fig. 2 Clinical outcome of SHON protein nuclear expression in breast cancer. 
Kaplan-Meier plots of the rates of breast cancer specific survival (BCSS; months) in 
the NUH-ES-BC cohort (n=1,650) according to SHON protein nuclear expression 
(SHON-Nuc) status. The p value from the log rank test is shown in each panel; 'n' is 
the number of samples in each group. High risk, NPI scores ≥ 3.4; ERα, estrogen 
receptor α; +, positive expression; -, negative expression. 
Fig. 3 Clinical outcome of SHON protein cytoplasmic expression in breast 
cancer. Kaplan-Meier plots of the rates of breast cancer specific survival (BCSS; 
months) in the NUH-ES-BC cohort (n=1,650) according to SHON protein cytoplasmic 
expression (SHON-Cyto) status. The p value from the log rank test is shown in each 
panel; 'n' is the number of samples in each group. High risk, NPI scores ≥ 3.4; ERα, 
estrogen receptor α; +, positive expression; -, negative expression. 
Fig. 4 Clinical outcome of SHON protein cytoplasmic expression in ERα- breast 
cancer patients. Kaplan-Meier plots of the rates of breast cancer specific survival 
(BCSS; months) in the NUH-ERα-ESBC cohort (n=697) according to SHON protein 
cytoplasmic expression (SHON-Cyto) status. The p value from the log rank test is 
shown in each panel; 'n' is the number of samples in each group. High risk, NPI 
scores ≥ 3.4; ERα, estrogen receptor α; +, positive expression; -, negative 
expression. 
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Fig. 5 Clinical outcome of SHON protein nuclear and cytoplasmic expression 
in the chemotherapy-treated patients. Kaplan-Meier plots of the rates of distant 
metastasis free survival (years) in the NUH-LABC cohort (n=117), who received 
neoadjuvant anthracycline based combination chemotherapy and if ERα+, followed 
by 5-year adjuvant tamoxifen, according to the status of SHON protein nuclear 
expression (SHON-Nuc) (a) and SHON protein cytoplasmic expression (SHON-Cyto) 
(b). The p value from the log rank test is shown in each panel; 'n' is the number of 
samples in each group. +, positive expression; -, negative expression. 
Fig. 6 Current understanding of SHON and ERα signalling. Classically, ERα 
signalling is initiated following the binding of estrogen (E2) to estrogen receptor, 
resulting in its translocation to nucleus and binding directly to estrogen response 
elements (EREs) on gene promoter of estrogen-regulated genes, which 
subsequently activate transcription of downstream genes. Anti-estrogen tamoxifen 
(Tam) competes with E2 for binding to ERα. SHON may bind to a yet-unknown 
receptor and activate PI3K/AKT and MAPK pathways that are linked to the action of 
ERα. SHON may also activate TGF-β pathway, resulting in SMAD2/3/4 translocation 
to nucleus and causing inhibition of ERα transcriptional activity upon Tam induction. 
Exogenous and/or intracellular pools of SHON may also enter the nucleus, thus 
enhancing the transcriptional activity of ERα. 
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Table 1. Association between SHON protein nuclear expression and clinicopathological 
variables in the NUH-ES-BC cohort (n=1,650). 
 
 
Variables 
SHON protein nuclear 
expression 
X2
p value (2 sided) 
Low 
N (%)
High 
N (%)
A) Pathological Parameters 
Lymph node (LN) Metastases    0.824 
Negative 753 (62.0) 28 (63.6) 
Positive 462 (38.0) 16 (36.4) 
Grade**   <0.001* 
Low (G1) 183 (15.1) 17 (38.6) 
Intermediate (G2) 373 (30.8) 20 (45.5) 
High (G3) 656 (54.1) 7 (15.9) 
Tumour Size (cm)   0.332 
T 1a+b(1.0) 120 (9.9) 6 (13.6) 
T 1c(>1.0-2.0) 596 (49.2) 26 (59.1) 
T2 (>2.0-5) 462 (38.1) 11 (25.0) 
T3 (>5) 34 (2.8) 1 (2.3) 
Mitotic Index 
M1 
M2 
M3 
 
370 (30.8) 
231 (19.2) 
600 (50.0) 
 
26 (61.9) 
8 (19.0) 
8 (19.0) 
<0.001* 
Pleomorphism 
P1 
P2 
P3 
 
24 (2.0) 
428 (35.6) 
749 (62.4) 
 
1 (2.4) 
29 (69.0) 
12 (28.6) 
<0.001*
Tubule Formation 
T1 
T2 
T3 
 
68 (5.7) 
394 (32.8) 
739 (61.5) 
 
2 (4.8) 
24 (57.1) 
16 (38.1) 
0.004*
Lympho-Vascular Invasion 
Positive 
Negative 
 
788 (65.8) 
410 (34.2)
 
30 (69.8) 
13 (30.2)
0.587 
Histological Type of Invasive Carcinoma   0.016*
Invasive ductal carcinoma -no special type 637 (61.5) 11 (36.7) 
Tubular Carcinoma 210 (20.3) 8 (26.7) 
Medullary carcinoma 25 (2.4) 0 (0.0) 
ILC 
Others 
79 (7.6) 
84 (8.1) 
5 (16.7) 
6 (20.0) 
B) Molecular Characteristics 
ERα (IHC) 
Negative 
 
348 (29.1) 
 
6 (14.6) 
0.044*
Positive 848 (70.9) 35 (85.4) 
PR (IHC) 
Negative 
 
507 (45.1) 
 
11 (28.9) 
0.049*
Positive 617 (54.9) 27 (71.1) 
HER2 Overexpression 
No 
 
1038 (87.7) 
145 (12.3) 
 
41 (97.6) 
1 (2.4) 
0.052 
Yes 
HER3 (IHC) 
Negative 
Positive 
 
474 (49.6) 
482 (50.4) 
 
16 (64.0) 
9 (36.0) 
0.155 
HER4 (IHC) 
Negative 
Positive 
 
401 (41.6) 
563 (58.4) 
 
19 (67.9) 
9 (32.1) 
0.006*
Androgen Receptor (IHC)   0.034*
2 
 
Negative 
Positive 
369 (39.1) 
574 (60.9) 
4 (17.4) 
19 (82.6) 
EGFR (IHC) 
Low 
High 
 
746 (79.7) 
190 (20.3) 
 
16 (80.0) 
4 (20.0) 
0.974 
MIB1 (Ki67) (IHC) 
Low 
High 
 
325 (32.4) 
679 (67.6) 
 
20 (58.8) 
14 (41.2) 
0.001*
BRCA1 (IHC) 
Absent 
Normal 
 
174 (20.4) 
677 (79.6) 
 
1 (5.3) 
18 (94.7) 
0.102 
SPAG5 (IHC) 
Low 
High 
 
696 (78.7) 
188 (21.3) 
 
24 (92.3) 
2 (7.7) 
0.093 
KIF2C (IHC) 
Low 
High 
 
264 (32.5) 
549 (67.5) 
 
17 (68.0) 
8 (32.0) 
<0.001*
PARP1 (IHC) 
Low 
High 
 
537 (73.5) 
194 (26.5) 
 
9 (47.4) 
10 (52.6) 
0.012*
TOPO2A (IHC) 
Low 
High 
 
398 (46.7) 
454 (53.3) 
 
3 (12.0) 
22 (88.0) 
0.001*
P53 (IHC) 
Low 
High 
 
754 (78.1) 
212 (21.9) 
 
20 (87.0) 
3 (13.0) 
0.306 
P27 (IHC) 
Low 
High 
 
444 (61.1) 
283 (38.9) 
 
9 (40.9) 
13 (59.1) 
0.057 
Cyclin B2 (IHC) 
Low 
High 
 
532 (44.2) 
671 (55.8) 
 
31 (72.1) 
12 (27.9) 
<0.001* 
MDM2 (IHC) 
Low 
High 
 
628 (75.3) 
206 (24.7) 
 
12 (66.7) 
6 (33.3) 
0.402 
MDM4 (IHC) 
Low 
High 
 
667 (62.9) 
393 (37.1) 
 
14 (42.4) 
19 (57.6) 
0.017*
P21 (IHC) 
Negative 
Positive 
 
474 (55.6) 
379 (44.4 
 
14 (66.7) 
7 (33.3) 
0.312 
P16 (IHC) 
Low 
High 
 
686 (84.4) 
127 (15.6) 
 
18 (81.8) 
4 (18.2) 
0.745 
P63 (IHC) 
Negative  
Positive 
 
978 (97.9) 
21 (2.1) 
 
28 (100.0) 
0 (0.0) 
0.438 
CDK1 (IHC) 
Low 
High 
 
506 (70.0) 
217 (30.0) 
 
10 (100) 
0 (0.0) 
0.039*
BCL2 (IHC) 
Low 
High 
 
385 (36.0) 
683 (64.0) 
 
6 (18.8) 
26 (81.3) 
0.044*
BAX (IHC) 
Low 
High 
 
465 (69.6) 
203 (30.4) 
 
13 (61.9) 
8 (38.1) 
0.451 
 
CK18 (IHC) 
Negative 
Positive 
 
108 (11.6) 
820 (88.4) 
 
2 (8.7) 
21 (91.3) 
0.663 
3 
 
CK19 (IHC) 
Negative 
Positive 
 
62 (6.2) 
644 (93.8) 
 
0 (0.0) 
26 (100.0) 
0.192 
CK14 (IHC) 
Negative 
Positive 
 
875 (87.1) 
130 (12.9) 
 
19 (70.4) 
8 (29.6) 
0.012*
CK6 (IHC) 
Negative 
Positive 
 
838 (82.7) 
175 (17.3) 
 
19 (70.4) 
8 (29.6) 
0.096 
SMA (IHC) 
Negative 
Positive 
 
846 (85.1) 
148 (14.9) 
 
23 (85.2) 
4 (14.8) 
0.991 
ERCC1 (IHC) 
Low 
High 
 
344 (61.2) 
218 (38.8 
 
4 (26.7) 
11 (73.3) 
0.007*
TDK (IHC) 
Low 
High 
 
461 (59.4) 
315 (40.6) 
 
18 (60.0) 
12 (40.0) 
0.948 
RECQL4 Cytoplasm (IHC) 
Low 
High 
 
122 (15.2) 
673 (84.7) 
 
7 (25.9) 
20 (74.1) 
0.137 
RECQL4 Nuclear (IHC) 
Low 
High 
 
405 (50.9) 
390 (49.1) 
 
6 (22.2) 
21 (77.8) 
0.003*
RECQL5 (IHC) 
Low 
High 
 
429 (47.9) 
466 (52.1) 
 
9 (28.1) 
23 (71.9) 
0.027*
Vimentin (IHC) 
Low 
High 
 
920 (88.6) 
118 (11.4) 
 
25 (86.2) 
4 (13.8) 
0.686 
E-cadherin (IHC) 
Negative 
Positive 
 
54 (5.5) 
931 (94.5) 
 
1 (4.0) 
24 (96.0) 
0.747 
BLM Cytoplasm (IHC) 
Low 
High 
 
418 (45.0) 
511 (55.0) 
 
20 (50.0) 
20 (50.0) 
0.533 
BLM Nuclear (IHC) 
Low 
High 
 
518 (55.8) 
411 (44.2) 
 
12 (30.0) 
28 (70.0) 
0.001*
CHK1 (IHC) 
Low 
High 
 
504 (52.5) 
456 (47.5) 
 
7 (28.0) 
18 (72.0) 
0.016*
ATM Cytoplasm (IHC) 
Low 
High 
 
392 (53.2) 
345 (46.8)
 
6 (40.0) 
9 (60.0)
0.311 
ATR (IHC) 
Low 
High 
 
623 (64.4) 
345 (35.6) 
 
28 (77.8) 
8 (22.2) 
0.098 
CHK2 (IHC) 
Low 
High 
 
389 (48.3) 
416 (51.7) 
 
5 (25.0) 
15 (75.0) 
0.039*
Phosphorylated ChK1 Nuclear (IHC)
Low 
High 
 
975 (85.9 
160 (14.1 
 
17 (38.6) 
27 (61.4) 
<0.001* 
Phosphorylated ChK1 Cytoplasm (IHC)
Low 
High 
 
359 (31.6) 
776 (68.4) 
 
17 (38.6) 
27 (61.4) 
0.328 
 
XRCC1 (IHC) 
Low 
 
142 (16.3) 
 
1 (4.3) 
0.122 
4 
 
High 728 (83.7) 22 (95.7) 
DNA Polymerase Beta (IHC) 
Low 
High 
 
396 (39.3) 
611 (60.7) 
 
7 (21.2) 
26 (78.8) 
0.036*
 
DNA PK (IHC) 
Low 
High 
 
317 (35.8) 
569 (64.2) 
 
8 (29.6) 
19 (70.4) 
0.511 
SMUG1 (IHC) 
Low 
High 
 
316 (40.7) 
461 (59.3) 
 
4 (20.0) 
16 (80.0) 
0.063 
APE1 (IHC) 
Low 
High 
 
493 (52.1) 
454 (47.9) 
 
9 (28.1) 
23 (71.9) 
0.008*
FEN1 (IHC) 
Low 
High 
 
606 (74.1) 
212 (25.9) 
 
8 (36.4) 
14 (63.6) 
<0.001* 
Phosphorylated c-Jun (IHC) 
Low 
High 
 
439 (46.7) 
501 (53.3) 
 
7 (25.0) 
21 (75.0) 
0.023*
Phosphorylated JNK (IHC) 
Low 
High 
 
661 (72.2) 
255 (27.8) 
 
9 (39.1) 
14 (60.9) 
0.001*
Phosphorylated p38 (IHC) 
Low 
High 
 
741 (84.1) 
140 (15.9) 
 
16 (69.6) 
7 (30.4) 
0.062 
SRC3 (IHC) 
Low 
High 
 
541 (57.2) 
405 (42.8) 
 
15 (62.5) 
9 (37.5) 
0.603 
 
S543 (IHC) 
Low 
High 
 
727 (82.9) 
150 (17.1) 
 
12 (54.5) 
10 (45.5) 
0.001*
ATF2 (IHC) 
Low  
High 
 
455 (49.2) 
469 (50.8) 
 
13 (52.0) 
12 (48.0) 
0.786 
T24 (IHC) 
Low  
High 
 
612 (74.6) 
208 (25.4) 
 
15 (78.9) 
4 (21.1) 
0.669 
T71 (IHC) 
Low  
High 
 
502 (50.6) 
490 (49.4) 
 
12 (40.0) 
18 (60.0) 
0.252 
HAGE (IHC) 
Negative  
Positive 
 
982 (90.8) 
100 (9.2) 
 
33 (94.3) 
2 (5.7) 
0.476 
TROAP (IHC) 
Negative  
Positive 
 
431 (55.7) 
343 (44.3) 
 
11 (47.8) 
12 (52.2) 
0.455 
Breast Cancer Sub-groups 
Luminal A 
Luminal B (Ki67>=15) 
Luminal B (HER2+) 
Non Luminal HER2+ 
Basal Like 
ER-/HER2- none basal 
 
348 (34.5) 
314 (31.1) 
63 (6.2) 
81 (8.0) 
155 (15.4) 
48 (4.8) 
 
24 (72.7) 
4 (12.1) 
0 (0.0) 
1 (3.0) 
4 (12.1) 
0 (0.0) 
0.001*
Basal Like Phenotype 
No 
Yes 
 
981 (86.4) 
155 (13.6) 
 
36 (90.0) 
4 (10.0) 
0.508 
Triple Negative Phenotype 
No  
Yes 
 
937 (79.5) 
241 (20.5) 
 
36 (90.0) 
4 (10.0) 
0.105 
5 
 
 
*Statistically significant at p<0.05; **Grade as defined by the Nottingham Grading System 
(NGS). ERα, estrogen receptor α; PR, progesterone receptor; HER2, human epidermal 
growth factor receptor 2; Triple negative, ERα-/PR-/HER2-.  
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Table 2. Association between SHON protein cytoplasmic expression and clinicopathological 
variables in the NUH-ES-BC cohort (n=1,650). 
 
 
Variables 
SHON protein cytoplasmic 
expression 
X2
p value (2 sided) 
Low 
N (%)
High 
N (%)
A) Pathological Parameters 
Lymph node (LN) Metastases    0.432 
Negative 343 (63.2) 457 (61.0) 
Positive 200 (36.8) 292 (39.0) 
Grade**   <0.001* 
Low (G1) 102 (18.8) 106 (14.2) 
Intermediate (G2) 192 (35.3) 213 (28.6) 
High (G3) 250 (46.0) 426 (57.2) 
Tumour Size (cm)   0.180 
T 1a+b(1.0) 49 (9.0) 80 (10.7) 
T 1c(>1.0-2.0) 286 (52.6) 286 (38.4) 
T2 (>2.0-5) 198 (36.4) 25 (3.4) 
T3 (>5) 11 (2.0) 25 (3.4) 
Mitotic Index 
M1 
M2 
M3 
 
208 (38.9) 
100 (18.7) 
227 (42.4) 
 
204 (27.6) 
143 (19.3) 
393 (53.1) 
<0.001* 
Pleomorphism 
P1 
P2 
P3 
 
13 (2.4) 
229 (42.8) 
293 (54.8) 
 
15 (2.0) 
240 (32.4) 
485 (65.5) 
<0.001*
Tubule Formation 
T1 
T2 
T3 
 
31 (5.8) 
189 (35.3) 
315 (58.9) 
 
43 (5.8) 
238 (32.2) 
459 (62.0) 
0.488 
Lympho-Vascular Invasion 
Positive 
Negative 
 
368 (68.8) 
167 (31.2)
 
477 (64.5) 
262 (35.5)
0.114 
Histological Type of Invasive Carcinoma   <0.001*
Invasive ductal carcinoma -no special type 256 (56.6) 409 (63.7) 
Tubular Carcinoma 86 (19.0) 138 (21.5) 
Medullary carcinoma 10 (2.2) 15 (2.3) 
ILC 
Others 
56 (12.4) 
44 (9.7) 
32 (5.0) 
48 (7.5) 
B) Molecular Characteristics 
ERα (IHC) 
Negative 
 
117 (21.8) 
 
224 (33.2) 
<0.001*
Positive 419 (78.2) 490 (66.8) 
PR (IHC) 
Negative 
 
210 (41.3) 
 
322 (47.0) 
0.048*
Positive 299 (58.7) 363 (55.4) 
HER2 Overexpression 
No 
 
485 (91.0) 
48 (9.0) 
 
624 (86.1) 
101 (13.9) 
0.008*
Yes 
HER3 (IHC) 
Negative 
Positive 
 
236 (56.7) 
180 (43.3) 
 
263 (44.9) 
323 (55.1) 
<0.001* 
HER4 (IHC) 
Negative 
Positive 
 
204 (47.3) 
227 (52.7) 
 
227 (38.7) 
360 (61.3) 
0.006*
Androgen Receptor (IHC)   0.580 
2 
 
Negative 
Positive 
156 (37.7) 
258 (62.3) 
229 (39.4) 
352 (60.6) 
EGFR (IHC) 
Low 
High 
 
335 83.8) 
65 (16.3) 
 
442 (76.3) 
137 (23.7) 
0.005*
MIB1 (Ki67) (IHC) 
Low 
High 
 
170 (38.7) 
269 (61.3) 
 
189 (30.1) 
438 (69.9) 
0.004*
BRCA1 (IHC) 
Absent 
Normal 
 
65 (18.1) 
295 (81.9) 
 
114 (21.5) 
416 (78.5) 
0.207 
SHON Nuclear (IHC) 
Negative  
Positive 
 
491 (93.3) 
35 (6.7) 
 
731 (98.8) 
9 (1.2) 
<0.001*
SPAG5 (IHC) 
Low 
High 
 
321 (82.5) 
68 (17.5) 
 
417 (76.7) 
127 (23.3 
0.03*
KIF2C (IHC) 
Low 
High 
 
138 (39.9) 
208 (60.1) 
 
155 (30.2) 
358 (69.8) 
0.003*
PARP1 (IHC) 
Low 
High 
 
245 (77.8) 
70 (22.2) 
 
314 (69.2) 
140 (ki67 
0.008*
TOPO2A (IHC) 
Low 
High 
 
174 (47.5) 
192 (52.5) 
 
236 (44.4) 
295 (55.6) 
0.360 
P53 (IHC) 
Low 
High 
 
338 (80.9) 
80 (19.1) 
 
460 (76.8) 
139 (23.2) 
0.121 
P27 (IHC) 
Low 
High 
 
198 (61.1) 
126 (38.9) 
 
227 (61.1) 
173 (38.9) 
0.997 
Cyclin B2 (IHC) 
Low 
High 
 
288 (54.3) 
242 (45.7) 
 
295 (39.4) 
453 (60.6) 
<0.001* 
MDM2 (IHC) 
Low 
High 
 
241 (68.7) 
110 (31.3) 
 
412 (79.2) 
108 (20.8) 
<0.001*
MDM4 (IHC) 
Low 
High 
 
314 (68.0) 
148 (32.0) 
 
386 (58.8) 
271 (41.2) 
0.002*
P21 (IHC) 
Negative 
Positive 
 
218 (59.7) 
147 (40.3) 
 
284 (53.5) 
247 (46.5) 
0.064 
P16 (IHC) 
Low 
High 
 
292 (86.1) 
47 (13.9) 
 
431 (83.4) 
86 (16.6) 
0.274
P63 (IHC) 
Negative  
Positive 
 
433 (98.0) 
9 (2.0) 
 
602 (98.0) 
12 (2.0) 
0.925 
CDK1 (IHC) 
Low 
High 
 
219 (77.9) 
62 (22.1) 
 
307 (65.7) 
160 (34.3) 
<0.001*
BCL2 (IHC) 
Low 
High 
 
159 (33.9) 
310 (66.1) 
 
240 (36.4) 
419 (63.6) 
0.384 
BAX (IHC) 
Low 
High 
 
209 (74.9) 
70 (25.1) 
 
282 (65.7) 
147 (34.3) 
0.01*
3 
 
CK18 (IHC) 
Negative 
Positive 
 
48 (11.9) 
355 (88.1) 
 
85 (11.3) 
510 (88.7) 
0.77 
CK19 (IHC) 
Negative 
Positive 
 
31 (7.0) 
411 (93.0) 
 
34 (5.5) 
585 (4.5) 
0.308 
CK14 (IHC) 
Negative 
Positive 
 
385 (87.7) 
54 (12.3) 
 
534 (85.9) 
88 (14.1) 
0.384 
CK6 (IHC) 
Negative 
Positive 
 
379 (85.2) 
66 (14.8) 
 
501 (80.3) 
123 (19.7) 
0.039*
SMA (IHC) 
Negative 
Positive 
 
385 (87.5) 
55 (12.5) 
 
505 (82.8) 
105 (17.2) 
0.036*
ERCC1 (IHC) 
Low 
High 
 
151 (64.5) 
83 (35.5) 
 
200 (57.3) 
149 (42.7) 
0.081 
TDK (IHC) 
Low 
High 
 
211 (61.2) 
134 (38.8) 
 
278 (58.3) 
199 (41.7) 
0.407 
RECQL4 Cytoplasm (IHC) 
Low 
High 
 
81 (24.3) 
252 (75.7) 
 
51 (10.1) 
453 (89.9) 
<0.001* 
RECQL4 Nuclear (IHC) 
Low 
High 
 
167 (50.2) 
166 (49.8) 
 
251 (49.8) 
253 (50.2) 
0.921 
RECQL5 (IHC) 
Low 
High 
 
204 (51.4) 
193 (48.6) 
 
243 (43.9) 
310 (56.1) 
0.023*
Vimentin (IHC) 
Low 
High 
 
400 (89.1) 
49 (10.9) 
 
566 (88.2) 
76 (11.8) 
0.637 
E-cadherin (IHC) 
Negative 
Positive 
 
28 (6.5) 
402 (93.5) 
 
29 (4.8) 
580 (95.2) 
0.223 
BLM Cytoplasm (IHC) 
Low 
High 
 
228 (53.6) 
197 (46.4) 
 
219 (38.8) 
345 (61.2) 
<0.001* 
BLM Nuclear (IHC) 
Low 
High 
 
231 (54.4) 
194 (45.6) 
 
313 (55.5) 
251 (44.5) 
0.720 
CHK1 (IHC) 
Low 
High 
 
219 (53.9) 
187 (46.1)
 
300 (49.9) 
301 (50.1)
0.210 
ATM Cytoplasm (IHC) 
Low 
High 
 
166 (52.7) 
149 (47.3) 
 
243 (53.1) 
215 (46.9) 
0.922 
ATR (IHC) 
Low 
High 
 
294 (69.7) 
128 (30.3) 
 
373 (62.0) 
229 (38.0) 
0.011*
CHK2 (IHC) 
Low 
High 
 
187 (55.3) 
151 (44.7 
 
215 (42.6) 
290 (57.4 
<0.001* 
Phosphorylated ChK1 Nuclear (IHC)
Low 
High 
 
433 (85.7) 
72 (14.3) 
 
586 (83.1) 
119 (16.9) 
0.217 
Phosphorylated ChK1 Cytoplasm (IHC)
Low 
 
215 (42.6) 
 
174 (24.7) 
<0.001* 
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High 290 (57.4) 531 (75.3) 
XRCC1 (IHC) 
Low 
High 
 
64 (16.8) 
316 (83.2) 
 
82 (15.4) 
452 (84.6) 
0.546 
DNA Polymerase Beta (IHC) 
Low 
High 
 
201 (45.4) 
242 (54.6) 
 
213 (34.2) 
409 (65.8) 
<0.001* 
DNA PK (IHC) 
Low 
High 
 
176 (46.0) 
207 (54.0) 
 
154 (28.1) 
394 (71.9) 
<0.001* 
SMUG1 (IHC) 
Low 
High 
 
124 (36.6) 
215 (63.4) 
 
203 (42.4) 
276 (57.6) 
0.095 
APE1 (IHC) 
Low 
High 
 
254 (61.5) 
159 (38.5) 
 
260 (44.3) 
327 (55.7) 
<0.001*
FEN1 (IHC) 
Low 
High 
 
261 (73.7) 
93 (26.3) 
 
368 (72.9) 
137 (27.1) 
0.780 
Phosphorylated c-Jun (IHC) 
Low 
High 
 
209 (50.9) 
202 (49.1) 
 
253 (43.5) 
328 (56.5) 
0.023*
Phosphorylated JNK (IHC) 
Low 
High 
 
294 (73.3) 
107 (26.7) 
 
392 (70.1) 
167 (29.9) 
0.280 
Phosphorylated p38 (IHC) 
Low 
High 
 
322 (85.0) 
57 (15.0) 
 
457 (83.5) 
90 (16.5) 
0.563 
SRC3 (IHC) 
Low 
High 
 
249 (60.6)  
162 (39.4) 
 
319 (55.0) 
261 (45.0) 
0.08 
S543 (IHC) 
Low 
High 
 
310 (82.2) 
67 (17.8) 
 
448 (82.7) 
94 (17.3) 
0.866 
ATF2 (IHC) 
Low  
High 
 
204 (51.4) 
193 (48.6) 
 
277 (48.2) 
298 (51.8) 
0.325 
T24 (IHC) 
Low  
High 
 
261 (75.4) 
85 (24.6) 
 
384 (75.0) 
128 (25.0) 
0.885 
T71 (IHC) 
Low  
High 
 
237 (55.0) 
194 (45.0) 
 
293 (47.3) 
326 (52.7) 
0.015*
HAGE (IHC) 
Negative  
Positive 
 
440 (90.9) 
44 (9.1) 
 
602 (90.8) 
61 (9.2) 
0.949 
TROAP (IHC) 
Negative  
Positive 
 
216 (62.8) 
128 (37.2) 
 
241 (50.6) 
235 (49.4) 
0.001*
Breast Cancer Sub-groups 
Luminal A 
Luminal B (Ki67>=15) 
Luminal B (HER2+) 
Non Luminal HER2+ 
Basal Like 
ER-/HER2- none basal 
 
184 (41.2) 
142 (31.8) 
27 (6.0) 
21 (4.7) 
52 (11.6) 
21 (4.7) 
 
202 (32.4) 
181 (29.1) 
38 (6.1) 
62 (10.0) 
111 (17.8) 
29 (4.7) 
0.001*
Basal Like Phenotype 
No 
Yes 
 
463 (89.9) 
52 (10.1) 
 
583 (84.0) 
111 (16.0) 
0.003*
5 
 
Triple Negative Phenotype 
No  
Yes 
 
441 (83.7) 
68 (16.3) 
 
559 (77.2) 
165 (22.8) 
0.005*
 
*Statistically significant at p<0.05; **Grade as defined by the Nottingham Grading System 
(NGS). ERα, estrogen receptor α; PR, progesterone receptor; HER2, human epidermal 
growth factor receptor 2; Triple negative, ERα-/PR-/HER2-.  
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Table 3. Multivariate Cox regression model analyses for distant metastasis free 
survival in the NUH-LABC cohort (n=117). 
 
Variables OR 95% CI p value 
Lower Upper 
SHON cytoplasmic expression (high)  7.06 1.13 44.52 0.037* 
Adjuvant tamoxifen endocrine therapy 0.01 0.001 0.11 0.061 
ERα status 13.90 2.26 85.63 0.005** 
Post chemotherapy lymph node status 0.999 0.995 1.003 0.697 
Post chemotherapy lymph vascular 
invasion 
1.003 0.999 1.007 0.090 
Residual tumour size (mm) 1.002 0.998 1.005 0.287 
Histological grade 0.807 0.390 1.673 0.565 
HER2 status 1.020 0.414 2.513 0.966 
ERα*SHON nuclear expression interaction  0.005** 
ERα*SHON cytoplasmic expression 
Interaction 
 0.065 
Adjuvant tamoxifen *SHON nuclear 
expression interaction 
 0.007** 
ERα, estrogen receptor α; HER2, human epidermal growth factor receptor 2; *, 
p<0·05; **, p<0·01.  
1 
 
Table 4. Multivariate logistic regression model analyses for pCR in the NUH-LABC 
cohort (n=117). 
 
Variables OR 95% CI p value 
Lower Upper 
SHON cytoplasmic expression (high)  5.22 1.03 26.47 0.046* 
ERα status (positive) 0.30 0.078  1.152 0.079 
HER2 status (overexpression) 0.80 0.14 4.57 0.804 
SPAG5 (overexpression) 4.84 1.274 18.36 0.021* 
ERα, estrogen receptor α; HER2, human epidermal growth factor receptor 2; 
SPAG5, sperm-associated antigen 5. *, p<0·05. 
 
ERα positive breast cancer showing 
strong SHON nuclear staining and 
moderate cytoplasmic staining 
No primary antibody added 
ERα negative breast cancer showing no 
SHON nuclear staining but moderate  
cytoplasmic staining 
ERα negative breast cancer showing 
negative SHON nuclear staining and weak 
cytoplasmic staining 
ERα negative breast cancer showing 
negative SHON nuclear and strong 
cytoplasmic staining 
ERα positive breast cancer showing negative 
SHON nuclear staining and weak cytoplasmic 
staining 
SHON-Nuc+ (n=200) 
SHON-Nuc- (n=1075) 
Log rank=18.95, p=0.000014 
SHON-Nuc+ vs. SHON-Nuc- 
HR (95% CI)=0.66 (0.55-0.80), p=0.00003 
Figure 2 
SHON-Nuc+ (n=96) 
SHON-Nuc- (n=281) 
Log rank=6.8, p=0.009 
SHON-Nuc+ vs. SHON-Nuc- 
HR (95% CI)=0.53 (0.32-0.88), p=0.015 
SHON-Nuc+ (n=177) 
SHON-Nuc- (n=734) 
Log rank=20.08, p=0.000007 
SHON-Nuc+ vs. SHON-Nuc- 
HR (95% CI)=0.61 (0.48-0.76), p=0.00002 
SHON-Nuc+ (n=27) 
SHON-Nuc- (n=171) 
Log rank=0.0, p= 0.998 
SHON-Nuc+  vs. SHON-Nuc- 
HR (95% CI)=1.00 (0.73-1.37), 
p=0.998 
High risk/ERα+ 
No Endocrine therapy  
High risk/ERα+  
Endocrine therapy  
High risk/ERα+  
SHON-Nuc- 
High risk/ERα+  
SHON-Nuc+ 
SHON-Nuc+ (n=58) 
SHON-Nuc- (n=304) 
Log rank=14.43, p= 0.001 
SHON-Nuc+  vs. SHON-Nuc- 
HR (95% CI)=0.52 (0.34-0.78), 
p=0.002 
Endocrine therapy (n=58) 
No endocrine therapy (n=27) 
Log rank=14.43, p=0.001 
SHON-Nuc+ vs. SHON-Nuc- 
HR (95% CI)=0.21 (0.08-0.56), 
p=0.002 
Endocrine therapy (n=304) 
No endocrine therapy (n=171) 
Log rank=1.07, p= 0.300 
SHON-Nuc+  vs. SHON-Nuc- 
HR (95% CI)=0.85 (0.63-1.16), 
p=0.302 
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